Antipress Capsule (Fluoxetine Hydrochloride)

Adult dosage

Adults 1. Depression 1) Initial treatment: The initial dose is fluoxetine hydrochloride 20mg orally once daily in the morning. In controlled clinical trials, doses of 20～80mg daily were administered. If no improvement is observed, an increase in dose may be considered after several weeks. Doses exceeding 20mg daily should be given twice daily (morning and noon), and the maximum dose of 80mg daily must not be exceeded. The onset of an adequate antidepressant effect may be delayed until 4 weeks of treatment or longer. 2) Maintenance/continuation/extended treatment: There are no definitive data on how long patients should be treated with this medicine, but psychopharmacologists recognize that acute symptoms of depression require treatment for several months or longer. It is unknown whether the amount of antidepressant needed to relieve symptoms is the same as that needed to maintain or sustain remission. 2. Bulimia nervosa Administer 60mg of this medicine daily. The daily dose must not exceed 80mg. Measure electrolyte levels before starting treatment. 3. Obsessive-compulsive disorder Administer 20～60mg of this medicine daily. The daily dose must not exceed 80mg. 4. Premenstrual dysphoric disorder Administer 20mg of this medicine daily. After 6 months of treatment, reassess whether continued treatment is needed. Patients with renal and/or hepatic impairment, patients taking multiple medicines, elderly patients, and patients with comorbidities: Use a lower dose or reduce the frequency of administration. Adjust the dose appropriately according to age and symptoms. Switching from or to MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this medicine, allow an interval of at least 14 days. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 5 weeks must have elapsed after discontinuing this medicine. Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue must not start treatment with this medicine because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization or other interventional procedures, treatment should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medicine. If there is no alternative to linezolid or intravenous methylene blue and, for a particular patient, the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome, discontinue this medicine immediately and administer linezolid or intravenous methylene blue. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administration of linezolid or intravenous methylene blue, or for 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with methylene blue administered by a non-intravenous route (oral tablets or local injection) or with intravenous administration of this medicine at a dose of 1mg/kg or less is unclear. Nevertheless, clinicians should be aware of the potential for emergency symptoms of serotonin syndrome with such use.

This medication is primarily used to treat psychiatric disorders associated with depression. It may increase the risk of suicidal thoughts or behaviors, especially in children, adolescents, and young adults, so close observation and a physician's judgment are necessary when administering to this age group. During treatment with this medication, family members or caregivers should carefully monitor for changes in behavior such as suicidal thoughts or behaviors, aggression, and anger. If abnormal symptoms appear, immediate consultation with a physician is necessary. This medication should not be administered to patients with specific diseases or conditions, including those with hypersensitivity to this medication or its components, severe renal impairment, and those taking MAO inhibitors. Additionally, it should not be given to patients with lactose intolerance or certain genetic metabolic disorders. It should be administered with caution to patients with a history of seizures or suicidal tendencies, and treatment should be discontinued immediately if symptoms worsen or seizures occur. Patients with cardiovascular diseases or problems with liver or kidney function should also use this medication cautiously, and dosage adjustments may be necessary. This medication can affect blood glucose control; therefore, diabetics should regularly check their blood sugar levels. Patients with glaucoma should also be cautious, as there is a risk of pupil dilation and increased intraocular pressure. This medication contains the dye Yellow No. 5, so patients with allergic reactions to this component should be administered it with care. Common side effects include headaches, nausea, insomnia, fatigue, and diarrhea; however, there may be rare but serious reactions such as severe allergic reactions, bleeding, or liver function abnormalities. Particularly at the beginning of treatment or when changing dosages, the risk of suicide may increase, so patients and caregivers should be closely monitored. Sudden discontinuation of this medication may result in withdrawal symptoms such as dizziness, sensory disturbances, anxiety, nausea, and headaches, so dosage should be tapered under a physician's guidance. As this medication may interact with others, any concurrent medications should be disclosed to the physician or pharmacist, and alcohol consumption should be avoided. During pregnancy, it should be used only when absolutely necessary, considering the risks to the fetus, and during breastfeeding, the physician should be consulted prior to use. Safety in children and adolescents has not been established, so administration is not recommended. No specific age-related side effects have been reported in the elderly, but caution should be exercised considering potential interactions with other diseases or medications. In cases of overdose, serious symptoms such as nausea, vomiting, seizures, and cardiac arrhythmias may appear, requiring immediate medical attention; there is no specific antidote for this medication. This medication should be stored out of reach of children, and it is advisable not to transfer it to another container.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylactic reaction, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, nervousness, restlessness, tension, decreased libido, sleep disturbances, abnormal dreams, depersonalization, elevated mood, euphoric mood, thought disturbances, abnormal libido, bruxism, hypomania, mania, hallucinations, agitation, panic attacks, suicidal thoughts and behaviors, confusion, attention deficit, dizziness, taste disturbances, somnolence, drowsiness, tremors, psychomotor agitation, movement disorders, ataxia, balance disorders, tonic-clonic convulsions, convulsions, akathisia, Buccoglossal syndrome, serotonin syndrome, memory disturbances, blurred vision, mydriasis, palpitations, ventricular arrhythmia, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, events related to the lungs, epistaxis, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, urticaria, pruritus, hyperhidrosis, alopecia, increased tendency for bruising, diaphoresis, angioedema, petechiae, phototoxic reactions, purpura, erythema multiforme, arthralgia, myoclonus, myalgia, frequent urination, dysuria, urinary retention, urinary disorders, gynecological bleeding, erectile dysfunction, ejaculation disorders, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, anxious mood, chills, lethargy, abnormal mood, cold sensation, hot sensation, mucosal bleeding, weight loss, abnormal liver function tests, aplastic anemia, atrial fibrillation, cataract, cerebrovascular accident, cholestatic jaundice, dyskinesia, eosinophilic pneumonia, epithelial necrosis, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, movement disorders, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, Stevens-Johnson syndrome, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior, dizziness, sensory disturbances, sleep disturbances, weakness, agitation, anxiety, tremors, headache, rash, anaphylactoid reaction, progressive systemic reaction, severe reactions related to skin, kidneys, liver, or lungs, suicidal ideation, suicidal behavior, fractures, withdrawal symptoms, changes in platelet function, bleeding, akathisia, psychomotor restlessness

This medication should be stored in a sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1°C and 30°C room temperature to preserve the effectiveness and safety of the medication.

Appearance

Hard gelatin capsules filled with white to grayish powder, with a yellowish tint to the upper and lower parts.

Package unit

30 capsules/bottle, 100 capsules/bottle